Shots:
- Lundbeck has reported primary P-IIb (PROCEED) trial data assessing bocunebart (Lu AG09222, QM, SC or IV) vs PBO as a preventive treatment in pts with 1-4 prior preventive migraine treatment failures
- In the IV group (n=429), bocunebart met its 1EP, reducing monthly migraine days over Wks. 1-12, with a mean reduction of 4.24 vs 2.86 days. In pooled P-II data, pts with prior treatment failures achieved a mean reduction of 5.94 vs 3.63 monthly migraine days
- Based on the data, Lundbeck is advancing plans for further clinical development of bocunebart in migraine prevention. Also, Lundbeck presented P-I data, which demonstrated safety & tolerability of bocunebart when administered with Ubrogepant
Ref: PRnewswire| Image: Lundbeck | Press Release
Related News: Lundbeck Partners with Cradle to Accelerate AI-Driven Biotherapeutics Discovery
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
